Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europe and Japan TUCSON, Ariz., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc. (CPP) and Tillotts Pharma AG (Tillotts), a wholly-owned subsidiary of Zeria Pharmaceutical Co., Ltd. (Zeria),...

Phase III Familial Adenomatous Polyposis (FAP) Trial Now Open for Enrollment TUCSON, Ariz., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc., (CPP) announced today the launch of a double-blind, randomized, Phase III trial of the efficacy and safety of...

Phase III Colon Cancer Prevention Therapy Trial Now Open for Enrollment TUCSON, Ariz., April 18, 2013 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc., (CPP) announced today the launch of a Phase III colon cancer prevention trial in collaboration with the...

Cancer Prevention Pharmaceuticals Announces Completion of Bridge Financing Round TUCSON, Ariz., Aug. 24, 2011 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc. (CPP) today announced that it had completed a bridge financing round. As a result, the Company now has...

Cancer Prevention Pharmaceuticals Receives Positive Scientific Advice From EMA for CPP-1X Phase III TRIAL in FAP TUCSON, Ariz., July 29, 2011 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc. (CPP) has received positive advice from the European Medicines Agency (EMA) regarding its Phase III trial in...